TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37384960

Group type: EXPERIMENTAL
Intervention: Safer Kids
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intervention as Usual (IAU)
Number of subjects: 112
Study: 37385070

Group type: EXPERIMENTAL
Intervention: Early relapse (mTNBC)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Late relapse (mTNBC)
Number of subjects: 881
Study: 37385161

Group type: EXPERIMENTAL
Intervention: Peer mentor-led educational intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Training for mentors
Number of subjects: 30
Study: 37385272

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant VWF, 40 IU/kg over 5-10 min on day 1
Number of subjects: 39

Group type: COMPARATOR
Intervention: Oral tranexamic acid 1300 mg three times daily on days 1-5
Number of subjects: 39
Study: 37385275

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 938

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 938
Study: 37385278

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 50 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 37385279

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 25 mg
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 50 mg
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Oral semaglutide 14 mg
Number of subjects: 1606
Study: 37385280

Group type: EXPERIMENTAL
Intervention: Retatrutide
Number of subjects: 281

Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Retatrutide 0.5 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg escalation
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Retatrutide 4 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg slow escalation
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Retatrutide 8 mg fast escalation
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Retatrutide 12 mg escalation
Number of subjects: 281
Study: 37385475

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 75 mg monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 250 mg monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nucleos(t)ide analogue (NA) treatment
Number of subjects: 60
Study: 37385583

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study: 37385670

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37385675

Group type: EXPERIMENTAL
Intervention: Fibroblast Activation Protein (FAP) assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diagnostic methods
Number of subjects: 0
Study: 37385724

Group type: EXPERIMENTAL
Intervention: SEA-CD40 administered intravenously at doses of 0.6, 3, 10, 30, 45, and 60 µg/kg in 21-day cycles.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: SEA-CD40 administered intravenously at doses of 10-30 µg/kg.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: SEA-CD40 monotherapy.
Number of subjects: 67
Study: 37385747

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) - combination of aspirin and P2Y
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37385828

Group type: EXPERIMENTAL
Intervention: imlifidase
Number of subjects: 15
Study: 37385855

Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels monitoring
Number of subjects: 170
Study: 37385888

Group type: EXPERIMENTAL
Intervention: Moderna/mRNA1273, AstraZeneca/AZD1222, Janssen/Ad26.COV2.S, Novavax/NVX-CoV2373 (vaccine)
Number of subjects: 114480

Group type: EXPERIMENTAL
Intervention: Janssen/Ad26.COV2.S (vaccine)
Number of subjects: 114480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114480
Study: 37385905

Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 37385981

Group type: EXPERIMENTAL
Intervention: Salvage focal HIFU or cryotherapy (specific intervention details not provided)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Model performance assessment
Number of subjects: 168
Study: 37385995

Group type: EXPERIMENTAL
Intervention: Unecritinib 300 mg BID
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Unecritinib 100, 200, 300 mg QD and 200, 250, 300, 350 mg BID
Number of subjects: 147
Study: 37386016

Group type: EXPERIMENTAL
Intervention: Milademetan (MDM2i) with low-dose cytarabine (LDAC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Milademetan (MDM2i) with low-dose cytarabine (LDAC)±venetoclax
Number of subjects: 16
Study: 37386034

Group type: EXPERIMENTAL
Intervention: NPD group (n=28)
Number of subjects: 61

Group type: COMPARATOR
Intervention: non-NPD group (n=33)
Number of subjects: 61
Study: 37386363

Group type: EXPERIMENTAL
Intervention: Young-old group (65-74 years)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Old-old group (75-84 years)
Number of subjects: 62
Study: 37386368

Group type: EXPERIMENTAL
Intervention: Physical therapy-led triage
Number of subjects: 638

Group type: COMPARATOR
Intervention: Standard care assessment by an orthopedic surgeon
Number of subjects: 638
Study: 37386462

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (initial phase weeks 0-6)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve and previously medicated participants
Number of subjects: 144
Study: 37386473

Group type: EXPERIMENTAL
Intervention: Biomechanical-based Tai Chi training program, practiced thrice a week for 12 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular physical activity (PA) for at least 60 minutes, thrice a week for 12 weeks.
Number of subjects: 40
Study: 37386485

Group type: EXPERIMENTAL
Intervention: Markers of collagen turnover (PRO-C6 and C3M)
Number of subjects: 300
Study: 37386512

Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian dynamic model (HBDM) applied to Motor Activity Log (MAL) data from DOSE trial participants (0, 15, 30, or 60-h dose condition).
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian dynamic model (HBDM) applied to Motor Activity Log (MAL) data from EXCITE trial participants (60-h dose, immediate or delayed condition).
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Forecasting MAL of new participants using HBDM.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Hierarchical modeling for early training prediction.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Comparison of HBDM with static regression models and simpler dynamic models.
Number of subjects: 135
Study: 37386519

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 40 mg of hyperbaric prilocaine (Group A)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Local anesthesia with mepivacaine (Group B)
Number of subjects: 132
Study: 37386580

Group type: EXPERIMENTAL
Intervention: Fluid responsiveness assessment using stroke volume variation (SVV)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Diastolic function parameters (including mitral E/e' ratio)
Number of subjects: 57
Study: 37386582

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (DNMB) with rocuronium bolus at 1.2 mg/kg and maintenance dose of 0.3-0.6 mg/kg/h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (MNMB) with rocuronium bolus at 0.6 mg/kg and maintenance dose in boluses of 0.15-0.25 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (DNMB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (MNMB)
Number of subjects: 50
Study: 37386594

Group type: EXPERIMENTAL
Intervention: SPMs supplementation (n=23 subjects)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (n=28 subjects)
Number of subjects: 51
Study: 37386744

Group type: EXPERIMENTAL
Intervention: Indirect revascularization surgery (encephaloduroarteriosynangiosis - EDAS)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Indirect revascularization surgery (EDAS)
Number of subjects: 123
Study: 37386752

Group type: EXPERIMENTAL
Intervention: Customized healing abutment with connective tissue graft (CTG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Customized healing abutment without connective tissue graft (CTG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Customized healing abutment without CTG)
Number of subjects: 32
Study: 37387213

Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 37387272

Group type: EXPERIMENTAL
Intervention: Received breast milk at 7 months
Number of subjects: 999

Group type: COMPARATOR
Intervention: Did not receive breast milk at 7 months
Number of subjects: 999
Study: 37387399

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0
Study: 37387503

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 39
Study: 37387798

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine administration at 1.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37388217

Group type: EXPERIMENTAL
Intervention: IBD-Anti-inflammatory diet (IBD-AID) adapted for Puerto Ricans with CD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37388233

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HF-RT) - 40 Gy/15 fractions ± concomitant boost [8 Gy/15 fractions]
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CF-RT) - 50 Gy/25 fractions ± sequential boost [10 Gy/5 fractions]
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment using EORTC QLQ-C30 and QLQ-BR23
Number of subjects: 86
Study: 37388633

Group type: EXPERIMENTAL
Intervention: Flexitarian diet including approximately three serves of red meat (average of 390 g cooked weight per individual) per week
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vegetarian diet including plant-based meat alternatives (350-400 g per individual) per week
Number of subjects: 80
Study: 37388640

Group type: EXPERIMENTAL
Intervention: Higher plasma osteoprotegerin (OPG) levels
Number of subjects: 3766

Group type: EXPERIMENTAL
Intervention: Plasma OPG concentrations
Number of subjects: 3766
Study: 37388902

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_High expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_Low expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YAP1 expression levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YAP1_High tumors
Number of subjects: 0
Study: 37389016

Group type: EXPERIMENTAL
Intervention: Transplanting lungs from deceased donors with hepatitis C virus (HCV) infection
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transplanting HCV-RNA positive lungs
Number of subjects: 10
Study: 37389229

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve field stimulation (PENFS) for 6 consecutive weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve field stimulation (PENFS)
Number of subjects: 30
Study: 37389878

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy (iRARC)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 305
Study: 37389891

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 37389915

Group type: EXPERIMENTAL
Intervention: Purposeful Pathways intervention (augmented treatment condition)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 50
Study: 37389917

Group type: EXPERIMENTAL
Intervention: AF 5g (Predilife)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: AF 10g (Predilife)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: AF 5g (Predilife) + 10g MTDx
Number of subjects: 79

Group type: COMPARATOR
Intervention: PP 5g + 10g MTDx
Number of subjects: 79
Study: 37389933

Group type: EXPERIMENTAL
Intervention: m-RESIST intervention (smartwatch, mobile app, web-based platform, tailored therapeutic program)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: m-RESIST intervention
Number of subjects: 39
Study: 37389935

Group type: EXPERIMENTAL
Intervention: HIVST-chatbot
Number of subjects: 528

Group type: COMPARATOR
Intervention: HIVST-OIC
Number of subjects: 528
Study: 37390074

Group type: EXPERIMENTAL
Intervention: Silverman and Andersen index (SA index)
Number of subjects: 44
Study: 37390280

Group type: EXPERIMENTAL
Intervention: Endoscopic discectomy
Number of subjects: 470
Study: 37390310

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 529

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 529
Study: 37390360

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 113
Study: 37390376

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37390764

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (RAM + ERL)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo plus erlotinib (PBO + ERL)
Number of subjects: 386
Study: 37390799

Group type: EXPERIMENTAL
Intervention: Vitamin K Antagonist (VKA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 300

Group type: COMPARATOR
Intervention: Rivaroxaban, Apixaban, Edoxaban
Number of subjects: 300
Study: 37390800

Group type: EXPERIMENTAL
Intervention: ctDNA with a mutated allelic frequency (MAF) cut-off of 20%
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Combination of ctDNA MAF and carcinoembryonic antigen levels
Number of subjects: 412
Study: 37390805

Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention (US$175 in-kind loan for micro-irrigation pump, seeds, fertilizer, and training sessions)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Shamba Maisha intervention
Number of subjects: 377
Study: 37390836

Group type: EXPERIMENTAL
Intervention: ZPIV (two or three doses administered at days 0, 28, and 196-234)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ZPIV (third dose)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ZPIV (two doses)
Number of subjects: 75
Study: 37390864

Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (EFTR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 90
Study: 37390980

Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib (300 mg orally, twice daily)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Durvalumab plus Placebo
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib
Number of subjects: 401
Study: 37391055

Group type: EXPERIMENTAL
Intervention: Digital Gut-directed Hypnotherapy (GDH)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Digital Muscle Relaxation (MR)
Number of subjects: 362
Study: 37391056

Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg intravenous induction)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous 90 mg)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous 90 mg q8w)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study: 37391367

Group type: EXPERIMENTAL
Intervention: Daily written patient care updates
Number of subjects: 219

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 219
Study: 37391381

Group type: EXPERIMENTAL
Intervention: Rapid steroid withdrawal (RSWD)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy
Number of subjects: 587
Study: 37391470

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 37391523

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Femoral triangle block (FTB)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 78
Study: 37391547

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 3872
Study: 37391667

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Pirfenidone
Number of subjects: 0
Study: 37391729

Group type: EXPERIMENTAL
Intervention: Perioperative ketamine infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Placebo infusion (intraoperative and postoperative for up to 48 hours)
Number of subjects: 1544
Study: 37391738

Group type: EXPERIMENTAL
Intervention: Screening using a 30-s single-lead electrocardiogram (SL-ECG) during outpatient visits.
Number of subjects: 15393

Group type: EXPERIMENTAL
Intervention: Same-day 12-lead ECGs
Number of subjects: 15393

Group type: EXPERIMENTAL
Intervention: Survey of primary care practitioners (PCPs)
Number of subjects: 15393

Group type: EXPERIMENTAL
Intervention: Uncertainty regarding AF screening outside of office visits
Number of subjects: 15393
Study: 37391773

Group type: EXPERIMENTAL
Intervention: DigiKnowItNews: Teen (educational website)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control (no access to DigiKnowItNews: Teen during the study)
Number of subjects: 0
Study: 37391828

Group type: EXPERIMENTAL
Intervention: 5-MM group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ortho-k lenses with smaller BOZD
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Total HOAs, total SA, and primary SA
Number of subjects: 70
Study: 37391836

Group type: EXPERIMENTAL
Intervention: Tele-emergency medical service (n = 1544)
Number of subjects: 3531

Group type: COMPARATOR
Intervention: Conventional physician-based emergency medical service (control) (n = 1676)
Number of subjects: 3531
Study: 37391842

Group type: EXPERIMENTAL
Intervention: E-MinD Life programme
Number of subjects: 9
Study: 37391938

Group type: COMPARATOR
Intervention: Trifluridine/tipiracil alone (arm A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Panitumumab plus trifluridine/tipiracil (arm B)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge (fourth-line therapy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Other therapies (fourth-line therapy)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge (fourth-line treatment)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Other therapies (fourth-line treatment)
Number of subjects: 62
Study: 37392089

Group type: EXPERIMENTAL
Intervention: IV ketamine (twice-a-week for 4 weeks, then once-a-week for 4 weeks)
Number of subjects: 25
Study: 37392210

Group type: EXPERIMENTAL
Intervention: Gut microbiome intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gnotobiotic mouse modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metagenomic sequence analysis
Number of subjects: 0
Study: 37392268

Group type: EXPERIMENTAL
Intervention: Oral PrEP
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Disclosure experiences
Number of subjects: 119
Study: 37392274

Group type: EXPERIMENTAL
Intervention: Rectus muscle stretching technique
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard medial rectus recession (retrospective control)
Number of subjects: 7
Study: 37392342

Group type: EXPERIMENTAL
Intervention: Discrimination targeting Latino ethnic origin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Discrimination targeting undocumented residency status
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Discrimination targeting sexual orientation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy for problem solving
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy for stopping unpleasant emotions/thoughts
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy for getting social support
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Higher levels of coping self-efficacy
Number of subjects: 82
Study: 37392597

Group type: EXPERIMENTAL
Intervention: UB-311 (Q3M arm)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: UB-311 (Q6M arm)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (placebo arm)
Number of subjects: 43
Study: 37392783

Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with UMAs
Number of subjects: 468

Group type: COMPARATOR
Intervention: Oocyte donation in patients with normal uteri
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with a unicornuate uterus
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with UMAs without surgery
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Oocyte donation in patients with a partial septate uterus
Number of subjects: 468
Study: 37392789

Group type: EXPERIMENTAL
Intervention: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) 160/150/50 μg, once-daily (o.d.)
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) pooled (160/150/50 μg and 80/150/50 μg)
Number of subjects: 3065

Group type: COMPARATOR
Intervention: High-dose Mometasone/indacaterol (MF/IND) 320/150 μg, once-daily (o.d.)
Number of subjects: 3065

Group type: COMPARATOR
Intervention: High-dose Fluticasone/salmeterol (FLU/SAL) 500/50 μg, twice-daily (b.i.d.)
Number of subjects: 3065
Study: 37392954

Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD) with lumen-apposing metal stents (LAMSs)
Number of subjects: 48